| Value | ₹400.9 Cr |
|---|
BSE filing, NSE: SHRINGARMS. Summary written from the filing by ALFA Finder's alert engine.
Shringar House of Mangalsutra Ltd: key numbers
- Share price
- ₹273.61
- Market cap
- ₹2,638 Cr
- Revenue (annual)
- ₹2,246 Cr
- Net profit (annual)
- ₹115.5 Cr
- P/E (TTM)
- 21.8×Sector 50.0×
- Promoter holding
- 74.80%+0.00% QoQ
- FII holding
- 3.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shringar House of Mangalsutra Ltd
All →Shringar House of Mangalsutra Board Meeting Date
Shringar House of Mangalsutra Ltd intimated a board meeting on 04 November 2026 to consider standalone unaudited financial results for the quarter and half year ended 30 September 2026. The trading window remains closed until 48 hours after results announcement.
Shringar House of Mangalsutra Price Movement Clarification
Shringar House of Mangalsutra clarified that it is in compliance with SEBI regulations and aware of no undisclosed material information affecting its share price movement.
Shringar House of Mangalsutra Business Update
Shringar House of Mangalsutra Ltd. received the 'Mangalsutra Manufacturer of the Year' award at the 2026 India International Jewellery Awards.
Shringar House of Mangalsutra Other Announcement
Shringar House of Mangalsutra Ltd has filed the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Shringar House of Mangalsutra Annual General Meeting
Shringar House of Mangalsutra Limited held its 17th Annual General Meeting on September 28, 2026, to conduct business, including remuneration and borrowing limit approvals.
Shringar House of Mangalsutra Other Announcement
The company issued a notice to shareholders regarding the availability of its Integrated Annual Report for FY 2025-26 and the upcoming 17th Annual General Meeting.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr